Association of serum YKL-40 and DPP4 with T2-high asthma in Chinese adults
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc..
This study aimed to assess the utility of serum YKL-40 and serum dipeptidyl peptidase IV (DPP4) as biomarkers for distinguishing between type 2 (T2)-high and T2-low asthma in the Chinese population. Additionally, we sought to explore the associations of serum YKL-40 and DPP4 levels with asthma characteristics and conventional markers. A real-world observational cross-sectional study was conducted, involving a total of 75 adult asthma patients. We collected general information, including demographics and medical history. Measurements included complete blood count, fractional exhaled nitric oxide (FeNO), post-bronchodilator spirometry, serum YKL-40 and serum DPP4 levels. Asthma endotypes, T2-high and T2-low, were defined through a comprehensive review of existing literature and expert group discussions. Logistic and linear regression models were employed. Our findings indicated no significant association between serum YKL-40 or serum DPP4 levels and T2-high asthma across all models. In the fully adjusted model, their odds ratios (OR) were 0.967 (95% CI: 0.920-1.017) and 0.997 (95% CI: 0.993-1.001), respectively. Notably, serum YKL-40 exhibited a positive correlation with FeNO (β = 0.382, 95% CI: 0.230-0.533) after adjusting for confounding factors. This association, however, diminished in patients under 40 years old (P = .24), males (P = .25), and those with FEV1%pred of 80% or higher (P = .25). Serum DPP4 demonstrated a negative correlation with FEV1/FVC in the fully adjusted model (β: -0.005, 95% CI: -0.009, -0.000). Among Chinese adult asthma patients, a positive correlation was observed between serum YKL-40 levels and FeNO in females aged over 40 with FEV1%pred less than 80%. Additionally, a weak negative correlation was found between serum DPP4 levels and FEV1/FVC. However, neither serum YKL-40 nor serum DPP4 levels exhibited the capability to differentiate between T2-high and T2-low asthma.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
---|---|
Enthalten in: |
Medicine - 103(2024), 6 vom: 09. Feb., Seite e37169 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhang, Li [VerfasserIn] |
---|
Links: |
---|
Themen: |
31C4KY9ESH |
---|
Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1097/MD.0000000000037169 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368249115 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368249115 | ||
003 | DE-627 | ||
005 | 20240214233307.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240210s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/MD.0000000000037169 |2 doi | |
028 | 5 | 2 | |a pubmed24n1293.xml |
035 | |a (DE-627)NLM368249115 | ||
035 | |a (NLM)38335422 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhang, Li |e verfasserin |4 aut | |
245 | 1 | 0 | |a Association of serum YKL-40 and DPP4 with T2-high asthma in Chinese adults |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.02.2024 | ||
500 | |a Date Revised 14.02.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. | ||
520 | |a This study aimed to assess the utility of serum YKL-40 and serum dipeptidyl peptidase IV (DPP4) as biomarkers for distinguishing between type 2 (T2)-high and T2-low asthma in the Chinese population. Additionally, we sought to explore the associations of serum YKL-40 and DPP4 levels with asthma characteristics and conventional markers. A real-world observational cross-sectional study was conducted, involving a total of 75 adult asthma patients. We collected general information, including demographics and medical history. Measurements included complete blood count, fractional exhaled nitric oxide (FeNO), post-bronchodilator spirometry, serum YKL-40 and serum DPP4 levels. Asthma endotypes, T2-high and T2-low, were defined through a comprehensive review of existing literature and expert group discussions. Logistic and linear regression models were employed. Our findings indicated no significant association between serum YKL-40 or serum DPP4 levels and T2-high asthma across all models. In the fully adjusted model, their odds ratios (OR) were 0.967 (95% CI: 0.920-1.017) and 0.997 (95% CI: 0.993-1.001), respectively. Notably, serum YKL-40 exhibited a positive correlation with FeNO (β = 0.382, 95% CI: 0.230-0.533) after adjusting for confounding factors. This association, however, diminished in patients under 40 years old (P = .24), males (P = .25), and those with FEV1%pred of 80% or higher (P = .25). Serum DPP4 demonstrated a negative correlation with FEV1/FVC in the fully adjusted model (β: -0.005, 95% CI: -0.009, -0.000). Among Chinese adult asthma patients, a positive correlation was observed between serum YKL-40 levels and FeNO in females aged over 40 with FEV1%pred less than 80%. Additionally, a weak negative correlation was found between serum DPP4 levels and FEV1/FVC. However, neither serum YKL-40 nor serum DPP4 levels exhibited the capability to differentiate between T2-high and T2-low asthma | ||
650 | 4 | |a Review | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Dipeptidyl Peptidase 4 |2 NLM | |
650 | 7 | |a EC 3.4.14.5 |2 NLM | |
650 | 7 | |a Chitinase-3-Like Protein 1 |2 NLM | |
650 | 7 | |a Nitric Oxide |2 NLM | |
650 | 7 | |a 31C4KY9ESH |2 NLM | |
650 | 7 | |a Biomarkers |2 NLM | |
700 | 1 | |a Li, Liang |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Mei |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Qian-Yun |e verfasserin |4 aut | |
700 | 1 | |a Tang, Ji-Hong |e verfasserin |4 aut | |
700 | 1 | |a Liang, Mei |e verfasserin |4 aut | |
700 | 1 | |a Liu, Qin |e verfasserin |4 aut | |
700 | 1 | |a Fu, Xiao-Feng |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 103(2024), 6 vom: 09. Feb., Seite e37169 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
773 | 1 | 8 | |g volume:103 |g year:2024 |g number:6 |g day:09 |g month:02 |g pages:e37169 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000037169 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 103 |j 2024 |e 6 |b 09 |c 02 |h e37169 |